Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Aligos Therapeutics, Inc. (ALGS) reported a Q4 loss of $3.41 per share, which was worse than the Zacks Consensus Estimate of a $1.91 loss. This is an improvement from the $5.50 loss per share a year ago.
March 10, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aligos Therapeutics reported a Q4 loss of $3.41 per share, missing the Zacks Consensus Estimate of a $1.91 loss. This is an improvement from the previous year's $5.50 loss per share.
The reported loss per share of $3.41 is significantly worse than the expected loss of $1.91, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's $5.50 loss per share may provide some positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100